Overview
Poster sessions are designed to give presenters an opportunity to discuss informally their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

Poster Session
Posters will be displayed in Room 400A of the Quebec City Convention Centre from August 20-22. Each day will have a separate poster session. Posters for the specific day’s session must be removed that day.

Monday, August 20, Poster Session A
Tuesday, August 21, Poster Session B
Wednesday August 22, Poster Session C

1. Set Up
• 7:00am-8:00am. All posters must be up by 8:15am.

2. Hours
• Room 400A will be open for the attendees from:
  8:00am - 5:00pm ...............Monday and Tuesday
  8:00am -1:45pm ...............................Wednesday
• All breaks and lunches, as well as exhibits, will be held in Room 400A

3. Discussion Time
• General: Presenters should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45pm on Tuesday.

• Poster Walks – organized by the ISPE Special Interest Groups (SIG) Selected poster presenters in the categories of Drug Utilization (Monday); Molecular Epidemiology/Pharmacogenetics (Tuesday) and Medications in Pregnancy (Monday & Tuesday) will be invited to participate in the ISPE Special Interest Groups (SIG) poster walk.

The poster walks will offer presenters the opportunity to present their work and to discuss their results with an audience. Participants should be at their posters between 12:15-1:15pm (Monday & Wednesday), and 12:45-1:45 (Tuesday). When the poster walk chair and audience stop at your poster, please give a brief, 3-minute, presentation and to answer questions about your research

4. Poster Prizes
• A group of judges will select the best posters of each poster walk. The presenters will receive ribbons to display on the posters and an invitation to display their poster for the duration of the ICPE.

5. Take Down
• All posters must be taken down by 6:30 pm on Monday and Tuesday; posters must be taken down by 4:30pm on Wednesday.

• NOTE: ISPE and the Quebec City Convention Centre will not be responsible for any poster that is left up overnight or is lost or damaged.

Numbering System
• Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the Final Program, which will be available at the registration desk. The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number, for use in locating abstracts in the Final Program and the special issue of Pharmacoepidemiology and Drug Safety, is in brackets [ ] after the title of the abstract.

Poster Specifications
• Posters must be designed to fit a space 37 inches HIGH by 88 inches WIDE (0.94m HIGH by 2.2m WIDE). The board will be the only support device available. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.

• Poster Orientation: LANDSCAPE

• Posters may be attached to the boards using push pints or 2-sided Velcro tape. All poster presenters are encouraged to bring their own supplies.

• A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the 1-year period before the ICPE. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed.
OUTCOME
CONGRATULATES

Dr. Richard Gliklich, Dr. Nancy Dreyer
Principal Investigators, Senior Editors

&

AHRQ
Agency for Healthcare Research and Quality

FOR THE LANDMARK
FEDERAL HANDBOOK

"Registries for Evaluating Patient Outcomes: A User’s Guide"

"This new reference will be a tremendous resource to researchers, patient groups, health insurers, pharmaceutical companies and others who are eager to investigate which treatments work best... databases that depict outcomes in patient populations over time carry great potential for advancing the quality, safety and effectiveness of health care."

AHRQ Director
Carolyn M. Clancy, MD.

Released on May 16, 2007

©2007 Outcome Sciences, Inc. All Rights Reserved.
Drug Utilization Studies

1 The Impact of Rofecoxib Withdrawal in Canada and US: What Happened to Chronic Users of Cox-2 Selective Inhibitor (Coxib)? [166]
Yola Moride, Elham Rahme, Muhammad Mamdani, GRASP Study Group. (Canada)

2 Use of Coxibs and Traditional NSAIDs in Hospitalized Patients Prior to Rofecoxib Withdrawal: Utilization Pattern and Drug-Related Problems [167]
Kirsten K Viktil, Hege S Blix, Tron Moger, Aasmund Reikvam. (Norway)

3 Cox-2 Inhibitor Influence on Non-Steroidal Anti-Inflammatory Drug (NSAIDs) and Paracetamol Use in 6 Countries [168]
Nadia Barozzi, Susan E Tett. (Australia)

4 Prevalence and Costs of Concomitant Use of Alcohol in Medicaid Patients Dispensed Opioid Analgesics for Chronic Pain [169]
Meredith Y Smith, Liisa Palmer, Jay Margolis. (United States)

5 Implications of the Withdrawal of Rofecoxib from the Canadian Market: An Examination of Trends in Prescription Claims [170]
Olivier Desjardins, Jennifer Manley, Natasha Nanwa, Y Ingrid Goh, Ryan W Smith, Thomas R Einarson. (Canada)

6 Children’s Use of Medicine for Headache: Sources of Supply and Availability and Accessibility at Home [171]
Bjoern E Holstein, Anette Andersen, Rikke Kroener, Pernille Due, Ebba H Hansen. (Denmark)

7 The Value of Intensive Statin Treatment [172]
Marc Dorais, Stephane Rinfret, Jacques LeLorier. (Canada)

8 Quality of Cardiovascular Drug Prescribing in Croatia, 2001-2005 [173]
Daniijela Stimač, Josip Culić, Zvonimir Sostar, Mila Bucalić. (Croatia)

9 Prescribing Pattern of Statins in Taiwan: Analysis of National Claims Databases 2000-2004 [174]
Der-Chang Wung, Yea-Huei Kao, Swu-Jane Lin, Shu-Hwa Tai. (Taiwan)

10 Using Index Plots and Cumulative Incidence Curves to Visualize Patterns of Anti-Hypertensive Drug Use [175]
Douglas Gause. (United States)

11 Hypertension Management in Diabetic Patients: Prescribing Trends from 1999 to 2005 in Three Japanese University Hospitals [176]
Yukari Kamijima, Nobuhiro Ooba, Mitsunori Yagame, Kazuo Samizo, Yoshihiro Shimodzono, Shigeru Kageyama, Tadashi Kusunoki, Kiyoshi Kubota. (Japan)

12 Trends in Primary Care Prescribing for Patients with Heart Failure [177]
Heath F Heattle, Philip Woodvine, James Bashford, Tracy Savage, Stephen R Chapman. (United Kingdom)

13 Evaluation of Adherence and Persistence with Statin Therapy in Northern Italy [178]
Salvatore Mannino, Alfredo Cocci, Luigi Ablondi, Erminio Ebbli, Marco Villa. (Italy)

14 Driving Forces behind the Increasing Cardiovascular Treatment Intensity. A Dynamic Epidemiologic Model of Trends in Danish Cardiovascular Drug Utilization [179]
Helle W Kildemoes, Henrik Støvring, Morten Andersen. (Denmark)

15 Persistence of New Dopaminergic Agents in Clinical Practice Remarkably Comparable with Clinical Trial Data [180]
Maurits EL Arbouw, Kris LL Movig, Henk-Jan Guchelaar, Petra JE Poels, Jeroen PP van Vugt, Cees Neef, Toine CG Egberts. (Netherlands)

16 Treatment Patterns in Community Residents with Neuropathic Pain [181]
Louisa M Walsh, Barbara P Yawn, Peter Wollen, Prem Kumar, Gunnar P Brobert. (United States)

17 Isotretinoin Therapy and the Incidence of Acne Relapse: A Nested Case-Control Study [182]
Laurent Azoulay, Driss Oraichi, Anick Bérard. (Canada)

18 Self-Medication – A Qualitative Approach for the Study of Its Motivations [183]
Janeth OS Naves, Lia LC Castro, Edgar Merchan-Hamann, Christine MS Carvalho. (Brazil)

19 Medicine Use at Age 15 Strongly Predicts Medicine Use at Age 27 [184]
Anette Anderssen, Bjoern E Holstein, Pernille Due, Ebba H Hansen. (Denmark)

20 Is There an Association between the Range of Benzodiazepines Available and the Quality of Prescribing? An International Comparison [185]
Steve Kisely, Alesha Smith, Charmaine Cooke, Susan Tett, Ingrid Sketris, David Gardner. (Canada)
<table>
<thead>
<tr>
<th></th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Factors for Nonadherence to the Program for Arterial Hypertension Control in Campo Grande, MS, Brazil [186]</td>
<td>Maria L Oshiro, Lia LC Castro, Raquel Cymrot. (Brazil)</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Interactive Electronic Voting, Nominal Group Technique, and Non-Adherence to Guidelines: Interpreting Prescribing Behavior by Confronting MDs with the Pharmacoepidemiology Data They Generate [187]</td>
<td>Natan R Kahan, Dan-Andrei Waitman, Baruch Weinreb, Ernesto Kahan, David P Chinitz. (Israel)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Characteristics of Medication Use of Frail Elderly Living at Home [189]</td>
<td>Monique M Elseviers, Robert H Vander Stichele. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>The Influence of Palliative Care on Prescribing in Nursing Home Residents [190]</td>
<td>Monique M Elseviers, Robert H Vander Stichele. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Polymedication in a French Community-Dwelling Elderly Population: Data from the 3C Study [191]</td>
<td>Fabienne Bazin, Pernelle Noize, Antoine Pariente, Jean-François Dartigues, Nicholas Moore. (France)</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Antihypertensive Prescriptions for Elderly Hypertensive Patients with or without Diabetes Mellitus in Primary Care Clinics [192]</td>
<td>Sun-Young Jung, Nam-Kyong Choi, Hwa-Jung Kim, Byung-Joo Park. (Republic of Korea)</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>Nursing Care for Medication in Community-Dwelling Elderly [193]</td>
<td>Monique M Elseviers. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>The Influence of Age on the Quality of Prescribing in Nursing Home Residents [194]</td>
<td>Monique M Elseviers, Robert H Vander Stichele. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Statins, NSAIDs, and Pancreatic Cancer [195]</td>
<td>Marc Dorais, Raja Tamaz, Agnes Rakel, Jacques LeLorier, Benoit Panzini. (Canada)</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>A Pilot Study to Evaluate Drug Utilization Patterns in Taiwan [196]</td>
<td>Chen-Chung Chang, Mei-Shu Lin, Jason Chang, Yea-huei Kao Yang, Fe-Lin Lin. (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Potentially Inappropriate Medication Use by M+C Beneficiaries in the Last Year of Life [197]</td>
<td>Cheryl Fahim, Joanne Lynn, Mike Finch, Danielle Doberman, Jon Gable. (United States)</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>Utilization of Antibesity Medicines in Sweden [198]</td>
<td>Mikael Hoffmann, Björn Wettermark. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>Drug Utilization Studies: Their Importance for Post-Marketing Surveillance [200]</td>
<td>Lia C Castro. (Brazil)</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Establishing a National Medicines Utilisation Unit for Scotland [201]</td>
<td>Sharon Hems, Marion Bennie. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Impact of the End of Phytotherapy Drugs’ Refund by the French National Health Insurance on Drugs’ Sales [202]</td>
<td>Lionel H Pazart, Jacques M Massol, Geoffroy Sainte Claire Deville, Thierry Devevey. (France)</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Impact of the End of Refund of Phytotherapy by French National Health Insurance on Use of Other Reimbursed Drugs [203]</td>
<td>Jacques M Massol, Lionel H Pazart, Geoffroy Sainte Claire Deville, Thierry Devevey. (France)</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Drugs Cost and Prescribed with Adherence to Primary Health Care Essential Drugs List at the Private Primary Health Care in Medan, Indonesia [204]</td>
<td>Renuka Murugesu, Delini Devi Ramadras, Erna Kristin, Jarir At Thobari, Iwan Dwiprahasto. (Indonesia)</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Patterns and Medical Resource Utilization after Generic Switching in Antiepileptic Drugs – A Review of the Quebec Experience [207]</td>
<td>Jacques Lelorier, Mei Sheng Duh, Pierre Emmanuel Paradis, Patrick Lefebvre, Véronique Lauzon, Ranjani Manjunath, Odile Sheehy. (Canada)</td>
<td></td>
</tr>
<tr>
<td>Poster Number</td>
<td>Title</td>
<td>Authors</td>
<td>Country</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>44</td>
<td>Satisfaction Survey of Patients Attending Sultan Qaboos University Hospital Pharmacy, Oman [209]</td>
<td>Wael H Al-Naeem, Muna Al-Jumaa, Amna Al-Hashar. (Oman)</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Using IMS Hospital Drug Issue Data to Enable Secondary Care Prescribers To Assist Primary Care Organisations with Their Objectives and Targets [210]</td>
<td>Philip S Woodvine, Ronald Pate, Stephen R Chapman. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>Development and Validation of Prescribing Indicators for Cardiovascular Risk Management in Type 2 Diabetes Mellitus Patients [213]</td>
<td>Liana Martirosyan, Jozé Braspennin, Petra Denig, Flora M Haaijer-Ruskamp. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Development of Prescribing Quality Indicators for Primary Care [214]</td>
<td>Annamaria Fagrell, Christina Edwards, Bodil Ericsson, Mikael Hoffmann, Åke Karlsson, Anna Lindhe, Christer Norman, Mikael Svensson, Björn Wettermark. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Use of the Swedish Prescribed Drug Register to Assess the Extent of Possible Misuse of Drugs – The Example of Tramadol [215]</td>
<td>Anders Sundström, Jonny Olsson, Andreas Leimanis, Lennart Waldenlind, Gunilla Sjölin-Forsberg, Persson Ingemar. (Sweden)</td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Validation of Attribution of Reimbursed Drug Prescriptions in Administrative Databases in Northern Italy [216]</td>
<td>Marco Villa, Alfredo Cocci, Luciana Beduschi, Andrea Belloli, Salvatore Mannino. (Italy)</td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>The BEERS Criteria for Inappropriate Geriatric Medication Use: Improving the Validity of International Comparisons by Linking to International Medication Classifications [217]</td>
<td>Pauline Deprez, Robert H Vander Stichele, Thierry Christiaens. (Belgium)</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>There is a Difference in Knowledge of Physicians and Pharmacists of the Key Components of a Detailed Medication History in a Developing Sub-Saharan Tertiary Care Setting? [219]</td>
<td>Kazeeem B Yusuff, Fola Tayo. (Nigeria)</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Patterns of Visudyne® Use Among Patients Enrolled in a US Health Insurance Database [220]</td>
<td>John Seeger, Sebastian Schneeweiss, Michael Doherty, Debashish Dey, Elena Rivero. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Trends in Drug Prescribing for Osteoporosis after Hip Fracture, 1995-2004 [222]</td>
<td>Suzanne M Cadarette, Jeffrey N Katz, M Alan Brookhart, Raisa Levin, Margaret R Stedman, Niteesh K Choudhry, Daniel H Solomon. (United States)</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Osteoporosis: Use of Bisphosphonates in Australia [223]</td>
<td>Samantha Hollingworth, Lisa Nissen, Emma Duncan, Inong Gunanti. (Australia)</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Baseline Characteristics of French Postmenopausal Women with Osteoporosis in the European Forsteo Observational Study (EFOS) [224]</td>
<td>Gerald Rajzbaum, Caroline Germa, Soyi Liu-Leage, Stéphanie Tcherny-Lessenot. (France)</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>OSSO Study: Factors Associated with Incident Fractures in Patients with Osteoporosis Enrolled in France – 12 Month Longitudinal Follow Up [225]</td>
<td>Patrice Fardellone, Caroline Germa, Soyi Liu-Leage, Stephanie Tcherny-Lessenot. (France)</td>
<td></td>
</tr>
</tbody>
</table>
62 Consumption and Economic Burden of Antidepressants in Chile: A Database Analysis [226]
Marcio Machado, Marcela Jiron, Ines Ruiz. (Canada)

63 Antipsychotic Medication Use in Australia [227]
Samantha Hollingworth, Lisa Nissen, Maxine Robinson, Wayne Hall. (Australia)

64 Combination Therapy with SSRIs and Other Antidepressants: Patterns of Use in Sweden [228]
Anders Sundström, Jonny Olsson, Andrejs Leimanis, Waldenlind Lennart, Ingemar Persson, Gunilla Sjölin-Forsberg. (Sweden)

65 Use of SSRIs among Children and Adolescents – An Analysis from Individual Prescription Data in Sweden [229]
Jonny Olsson, Anders Sundström, Andrejs Leimanis, Lennart Waldenlind, Gunilla Sjölin-Forsberg, Ingemar Persson. (Sweden)

66 Impact of Drug Side Effects on Treatment Satisfaction in Antidepressant Users [230]
Marc Van Audenrode, Jane Chang, Erick Moyneur, Mei Sheng Duh. (Canada)

67 Adherence to Asthma Controller Medication: Evidence from the French Health Insurance Data [231]
Philippe Latry, Marion Pinet, Anne Labat, Didier Kosselek, Jean-Pierre Magand, Karin Martin-Latry, Mathieu Molimard. (France)

Kejal Parikh, Bradley C Martin. (United States)
69 Use of Emergency Contraception Among Portuguese Women [233]
Ermelindo Fontes, Patricia Ferreira, José Pedro Guerreiro, Telma Costa, Ana Miranda. (Portugal)

70 Prevalences and Trends in Medication Use during Pregnancy and Lactation [234]
Marie-Pierre Gendron, Brigitte Martin, Driss Oraichi, Anick Berard. (Canada)

71 Antibiotic Use in a Private Tertiary Hospital [235]
Mengistu A Assres, Tiwari Pramil, Sonu Malhotra. (India)

72 Drug Price, Utilization and Spending for Antiretroviral Medications in U.S. Medicaid Programs from 1991 to 2005 [236]
Yonghua Jing, Patricja Klein, Christina ML Kelton, Xing Li, Jeff J Guo. (United States)

73 Price and Utilization of Oral Anti-Diabetic Medications from 1991 to 2005 in U.S. Medicaid Programs [237]
Xing Li, Michael Doherty, Christina ML Kelton, Yonghua Jing, Jeff J Guo. (United States)

74 Trends of Use Antidiabetic Drugs in Spain. 1998-2005 [238]
María I Jiménez-Serrania, Javier García del Pozo, Ramona Mateos-Campos. (Spain)

75 Intravenous Ciprofloxacin Utilization Review [239]
Donna O Lowe, Gary G Wong, Lesley Graham, James Murdoch, Sophia Cao, Jack Seki, Monique Pitre, James Brunton. (Canada)

83 Prospective Surveillance of Vaccine Safety Using the Self-Controlled Case Series Method [247]
Mounia N Hocine, Patrick Musonda, Paddy C Farrington. (United Kingdom)

84 Detection of Potential Signals for Drug-Drug Interactions Using FDA AERS Spontaneous Report Data [248]
Zhiping Huang, Helen Huang, Scott Chavers. (United States)

85 Determination of Pregnancy on the General Practice Research Database [249]
Julia M Snowball, Corinne S de Vries. (United Kingdom)

Methods

76 An Important Advantage of Propensity Score Methods Compared to Logistic Regression Analysis [240]
Edwin PMartens, Wiebe R Pestman, Anthonius de Boer, Svettana V Belitzer, Olaf H Klungel. (Netherlands)

77 Impact of Case-Control Designs on Outcome Estimates: A Study of Isotretinoin and the Risk of Psychotic Disorders [241]
Laurent Azoulay, Anick Berard. (Canada)

78 Impact of Operationalization of Longitudinal Blood Pressure on Adverse Outcomes [242]
Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)

79 Use of Average Surrogate Values Introduces Bias: A Simple Simulation [243]
Tobias Gerhard, Almut Winterstein, Jonathan Shuster, Julie Johnson, Abraham Hartzema, Carl Pepine. (United States)

80 Orthogonal Experimental Designs Disentangle Confounding in Database Studies [244]
Charlie H Goldsmith, Lehana Thabane, Gary Foster. (Canada)

81 Infant and Toddler Disease Score for Risk of Hospitalization Based on Data from Administrative Claims Is Useful for Pharmacoepidemiologic Studies [245]
Yann Mikaeloff, Yola Moride, Babak Khoshnood, Alain Weill, Gerard Breart. (France)

82 No Evidence for Anti-Inflammatory Effects of Statins for Rheumatoid Arthritis Patients in a Large Claims Database [246]
Sara Lodj, Stephen Evans, James Carpenter. (United Kingdom)

87 Determining Sample Size for Post-Marketing Surveillance of Rare Adverse Events [251]
Jianmin Wang, Beth Sherrill, William Irish. (United States)

88 Comparing Prevalence Estimates from U.S. Claims Data by Two Methods [252]
Julie M Zito, James J Korelitz, Satish Valluri, James F Gardner, James Bethel, Donald R Mattison. (United States)

89 An Interaction between Statins and Clopidogrel – A Cohort Study with Survival Time Analysis [253]
Ana Blagojevic, Nandini Dendukuri, Joseph A Delaney, Jean-Francois Boivin, James M Brophy. (Canada)
<table>
<thead>
<tr>
<th>Posters A Monday, August 20</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Psychotropics 1</strong></td>
</tr>
<tr>
<td>90 Patient and GP Characteristics Associated with Antidepressant Treatment in Depressed Patients: A Multilevel Analysis [254]</td>
</tr>
<tr>
<td>91 Lifetime Amphetamine Use Disorders among Obese Individuals with and without Other Substance Use Disorders and/or Mental Disorders [255]</td>
</tr>
<tr>
<td>92 Polypharmacy in the Treatment of Schizophrenia – A Psychopharmacoepidemiologic Study [256]</td>
</tr>
<tr>
<td>94 Preadmission Use of Antipsychotic Drugs Was Associated with Increased Short-Term Mortality after Peptic Ulcer Perforation [258]</td>
</tr>
<tr>
<td>95 The Use of Anti-Depressant Medication and Risk of Re-Operation Due to Post-Surgical Bleeding in Breast Cancer Patients [259]</td>
</tr>
<tr>
<td>96 Psychotropic Drugs Associated with QTc Prolongation [260]</td>
</tr>
<tr>
<td>98 Smoking and Alcohol Consumption and Subsequent Use of Psychotropic Medications – A Prospective Study of 10,513 Adolescents in Norway [262]</td>
</tr>
<tr>
<td>99 Hemorrhagic Stroke Associated with Antidepressant Use: Does Degree of Serotonin Reuptake Inhibition Matter? [263]</td>
</tr>
<tr>
<td>100 Misuse of High Dosage Buprenorphine: Comparison of Use’s Pattern between 2000 and 2005 [264]</td>
</tr>
<tr>
<td>101 Impact of Antidepressants on the Risk of Suicide in Patients with Depression in Real-Life Conditions: A Decision Analysis Model [265]</td>
</tr>
<tr>
<td>102 Leisure Activities and Psychotropic Drug Use in a French Community-Dwelling Elderly Population [266]</td>
</tr>
<tr>
<td>104 Association between Aggression and Medication Changes [268]</td>
</tr>
<tr>
<td>105 Trends in U.S. Prescriptions for Antidepressants in Children, Adolescents and Young Adults [269]</td>
</tr>
</tbody>
</table>
Birth Defects

107 Congenital Malformations in Children Born to Women with Asthma [271]
LJ Tata, SA Lewis, TM McKeever, CJP Smith, P Doyle, L Smeeth, JE Gibson, RB Hubbard. (United Kingdom)

108 Duration of Antidepressant Use during Pregnancy and Risk of Major Congenital Malformations [272]
Elodie Ramos, Martin St-André, Évelyne Rey, Driss Oraichi, Anick Bérard. (Canada)

109 Paroxetine Use in Pregnancy and Cardiovascular Defects [273]
Adrienne Einarson, Alessandra Pistelli, Marco DeSantis, Christina Chambers, Heli Malm, Wolfgang Paulus, Alice Panchaud, Deborah Kennedy, Thomas Einarson, Gideon Koren. (Canada)

110 Validation of Neural Tube Defects in the General Practice Research Database [274]
Scott Devine, Sue West, Susan Eaton, Andrew Olshan, John Thorp, Pat Tennis, Elizabeth Andrews. (United States)

111 Maternal Use of Oral Contraceptives during Pregnancy and Risk of Hypospadias in Male Offspring [275]
Pia Wogelius, Mette Nørgaard, Lars Pedersen, Henrik Toft Sørensen. (Denmark)

112 The Utility of the General Practice Research Database to Examine Selected Congenital Heart Defects – A Validation Study [276]
Keele E Wurst, Sara A Ephross, James Loehr, Douglas W Clark. (United States)

113 Uncontrolled Maternal Asthma during Pregnancy and the Risk of Perinatal Outcomes [277]
Faranak Firoozi, Francine M Ducharme, Catherine Lemiere, Marie-France Beauchesne, Anick Berard, Amélie Forget, Lucie Blais. (Canada)

114 Maternal Asthma Exacerbation during the First Trimester of Pregnancy and the Risk of Congenital Malformation [278]
Lucie Blais, Amélie Forget. (Canada)

115 Risk of Perinatal Mortality Associated with Asthma during Pregnancy [279]
Breton Marie-Claude, Beauchesne Marie-France, Lemiere Catherine, Forget Amelie, Blais Lucie. (Canada)

116 Effect of Smoking Cessation Interventions during Pregnancy on the Newborn [280]
Anick Berard, Evelyne Rey, Driss Oraichi. (Canada)

117 Effect of Gestational Use of Hypoglycaemic Agents and Insulin on Adequacy of Maternal Glycaemia Control and Birth Defect Rates [281]
Anick Berard, Ema Ferreira, Driss Oraichi. (Canada)

118 Assessing the Safety of Antiretroviral Drugs Used during Pregnancy: Evolution from Voluntary Registry to Post-Marketing Commitment [282]
Deborah L Covington, Hugh H Tilson, Heather Watts, Susan Sacks, Vani Vannappagari. (Canada)

119 Impact of Universal Health Care Coverage on Hospital Drug Utilization in Thailand [283]
Penkarn Kanjanarat, Almut Winterstein, Abraham Hartzema, Earlene Lipowski, Lili Tian. (Thailand)

120 Swedish Physicians’ Views on Responsibility of Prescribing Costs Related to Dispensed Prescriptions [284]
Karolina Andersson, Anders Carlsten, Tove Jörgensen. (Sweden)

121 New Drugs and Old Diseases: Trends in Brazil [285]
Carlos CF Vidotti, Lia LC Castro, Paulo F Almeida, Mariana HM Cunha, Rogerio Hoeferli. (Brazil)

122 Drug Safety Surveillance in China and Other Countries: A Review and Comparison [286]
Jeff J Guo, Wenmin Du, Yonghua Jing, Christina ML Kelton. (United States)

123 Clopidogrel Use Post-Stent in AMI Patients in Two Canadian Provinces [287]
Magda Melo, Alice Newman, Hassan Behlouli, Stephane Rinfret, Cynthia Jackevicius, Jack Tu, Virginie Demers, Helen Johansen, Karin Humphries, Jafna Cox, Dimitri Kalavrouziotis, Louise Pilote. (Canada)

124 Factors Related to Splitting Tablets of HMG-COA Reductase Inhibitors: A Population-Based Analysis in British Columbia [288]
Colin Dormuth, Sebastian Schneeweiss, Alan Brookhart, Ken Bassett, James Wright. (Canada)

125 The Impacts of National Health Insurance Reimbursement Price on the Utilization of Oral Hypoglycemic Agents for Ambulatory Care [272]
Pei-Chen Chen, Yea-Huei Kao Yang, Ya-Ming Liu. (Taiwan)
**Sustainable Access to Medicines**

126 Beneficiary’s Prescription Drugs Out-of-Pocket Spending: A Cross-Sectional Pilot Study in the Saudi Ministry of Health Hospital Outpatient Clinics [290]
Mohamed A Alkelya. (Saudi Arabia)

127 Cultural Context for Epidemiology: Qualitative Lessons from HIV and TB in South Africa (SA) [291]
Christi E Lane-Barlow, Paul E Stang. (South Africa)

128 Cost-Related Medication Underuse and Knowledge of Cost-Saving Strategies – A Qualitative Study [292]
Mark A Allen. (United States)

**Economics**

129 The Monetary Value of a Genetic Test To Identify the Patients Susceptible to Develop Statin-Induced Muscular Adverse Events [293]
Elisabeth Martin, Odyle Sheehy, Jacques Lelorier. (Canada)

130 Prevalence, Management, and Cost of Uncomplicated Gastroesophageal Reflux Disease in France: A Pharmacoeconomy Study [294]
Agnes Charlemagne, Philippe Lejeunne, Stephane Mouly. (France)

131 Costs of Non-Compliance and Non-Persistence with Medications for Diabetes Mellitus [295]
Maribel Salas, Kawitha Vardeva, Maximilian Lehmeyer, Dyfrig Hughes. (United States)

132 Evaluating the Quality of Economic Studies of Macular Degeneration Therapeutics [296]
Amalia M Issa, Todd Weiss, William J Foster. (United States)

133 Principal Components Analysis of Drug Expenditure Trends for All Major Therapeutic Classes in U.S. Medicaid Programs [297]
Yonghua Jing, Kiet Nguyen, Huilao Fan, Christina ML Kelton, Xing Li, Jeff J Guo. (United States)

134 Economic Unviable Prescriptions Do Not Drive Drug Expenditures Substantially in Germany [298]
Bertram Haeussler, Ariane Hoeer. (Germany)

135 Value and Types of Medicines Returned by Patients to Sultan Qaboos University Hospital Pharmacy, Oman [299]
Khalid H Al Siyabi, Kassim Al Riyami. (Oman)

136 A Decision-Model Assessing Cost-Effectiveness of Pharmacogenomic-Based Tests for Everyday Medical Practice [300]
Mathieu Beaulieu, Jean Lachaine. (Canada)

137 The Economic Consequences of Clopidogrel (Mis)Prescribing [301]
Niteesh K Choudhry, Raisa Levin, Jerry Avorn. (United States)

138 Infliximab Decreases Annual Corticosteroid Consumption in Crohn’s Disease Patients [302]
Amir Tahami Monfared, Edmond-Jean Bernard, Ernest G Seidman, Garon Edith, Theodoros Koulis, John S Sampalis. (Canada)

139 Infliximab Expenditures for the Management of Crohn’s Disease in Routine Clinical Practice in Quebec [303]
Amir Tahami Monfared, Edmond-Jean Bernard, Ernest G Seidman, Edith Garon, Theodoros Koulis, John S Sampalis. (Canada)
Molecular Epidemiology/Pharmacogenetics

1 Antiretroviral (ARV)-Resistance Testing and Frequency of ARV Resistance among ARV-Naïve Patients in the HOPS Cohort, 1999-2005 [304]
Benjamin Young, Rose K Baker, Douglas Ward, Kathy C Wood, John T Brooks, HIV Outpatient (HOPS Investigators). (United States)

2 Integrating Pharmacology with Pharmacovigilance: Developing Tools To Examine Pattern of Risks within Drug Classes in Prescription-Event Monitoring (PEM) [305]
Deborah Layton, Germano LC Ferreira, Saad AW Shakir. (United Kingdom)

3 Neutrophilia Is Not Associated with Complications during Hospitalisation [306]
Karin J Velthove, Madelon Bracke, René C Schweizer, Patrick C Souverein, Maarten J ten Berg, Hubert GM Leufkens, Wouter W van Solinge. (Netherlands)

4 Lessons Learned on the Design of a Pharmacogenomic Study [307]
Marie-Pierre Dubé, Dana S Aeschliman, Bruce C Carleton, Michael R Hayden. (Canada)

Medicines in Pregnancy

5 Metoclopramide and Diphenhydramine in the Treatment of Hyperemesis Gravidarum: Effectiveness, Safety, and Predictors of Rehospitalisation [308]
Anais Lacasse, Amandine Lagoutte, Ema Ferreira, Anick Berard. (Canada)

6 Over the Counter (OTC) Medications Use by Women of Childbearing Age in Southern Israel [309]
Ilan Matok, Raphael Gorodischer, Gideon Koren, Amalia Levy. (Israel)

7 Serotonin Selective Reuptake Inhibitor (SSRI) Use by Women of Childbearing Age in Southern Israel [310]
Ilan Matok, Raphael Gorodischer, Gideon Koren, Amalia Levy. (Israel)

8 Medication Use by Women of Childbearing Age in Southern Israel [311]
Ilan Matok, Raphael Gorodischer, Gideon Koren, Amalia Levy. (Israel)

9 Identification of Pregnancies in the Full Featured General Practice Research Database [312]
Scott Devine, Sue West, Susan Eaton, Andrew Olshan, John Thorp, Pat Tennis, Elizabeth Andrews. (United States)

10 Prescribing Patterns of Chronic and Short-Term Drugs before and during Pregnancy in Relation to Physician Diagnosed Indications: A General Practice Study [313]
Anita C Volkers, Mustafa Yucesa, Liset van Dijk. (Netherlands)

11 Selection of Controls in Case-Control Studies of Maternal Medication Use and Risk of Birth Defects [314]
Marian K Bakker, Hermien EK De Walle, Aliene Dequito, Paul B Van den Berg, Lolkje TW De Jong-Van den Berg. (Netherlands)

12 Validation of UK General Practice Research Database Mother-Baby Linkage Using a Sample of Congenital Heart Defect Records [315]
Keele E Wurst, Sara A Ephross. (United States)

13 Two-Stage Nested Case-Control Study of the Control and Severity of Maternal Asthma during Pregnancy and the Incidence of Asthma in the Offspring [316]
Marie-Josee Martel, Evelyne Rey, Marie-France Beauchesne, Jean-Luc Malo, Sylvie Perreault, Amelie Forget, Lucie Blais. (Canada)

14 Does Monetary Compensation Decrease Losses to Follow-Up in Pregnancy Exposure Registries? [317]
Susan S Roberts, Ann E Mallard, Sandra M Ferber, Deborah L Covington, Marianne C Cunnington. (United States)

Endocrine/Diabetes

15 Characterization of Oral Antidiabetic Usage Pattern among Type 2 Diabetic Patients: A General Practice Research Database Study [318]
Arshadul Haque, Songlin Xue, Syed S Islam. (United States)

16 Do Hand and Foot Fractures Increase the Likelihood of Future Hip Fractures in Type 2 Diabetic Subjects? [319]
Carol E Koro, Deanna Hill, Douglas Clark, Kathleen J Beach. (United States)
17 Impact of Oral Anti-Hyperglycemic (OAH) Therapy on All-Cause Mortality among Patients with Diabetes in the Veterans Health Administration (VHA) [320]
Kristian H Kahler, Mangala Rajan, George G Rhoads, Monika M Safford, Kitaw Demissie, Shou-En Lu, Leonard M Pogach. (United States)

18 Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents [321]
Andrew T McAfee, Carol Koro, Joan Landon, Najat Ziyadeh, Alexander M Walker. (United States)

19 Changes in LDL-Cholesterol Levels and Lipid Lowering Therapy in Primary Care between 2002 and 2006. The REALITY Studies [322]
Laurent Laforet, Thierry Souchet, Gaelle DeSamericq, Cecile Ritieng, Philippe Moulin, Alexia Kieffer, Philippe Le Jeunne, Eric Van Ganse. (France)

20 Influence of Polypharmacy on Adherence with Drug Use in Patients with Diabetes Mellitus Type 2: A Questionnaire Study [323]
Shireen S Ilahibaks, Jacqueline G Hugtenburg, Sander D Borgsteede. (Netherlands)

21 Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type 2 Diabetes Mellitus [324]
Matthijs L Becker, Loes E Visser, Paul H Trienekens, Bert Hofman, Ron HN van Schaik, Bruno HCH Stricker. (Netherlands)

22 Importance of Diabetes as a Risk Factor for Fractures after Solid Organ Transplantation [325]
Agnès Räkel, Odile Sheehy, Elham Rahme, Jacques LeLorier. (Canada)

23 Effect of Metformin on Serum Vitamin B12 and Homocysteine Levels in Patients with Type 2 Diabetes Mellitus in Saudi Arabia [326]
Areej A Al-Gadeer, Ahmed Y Mayt, Mohammed S Al-Sultan. (Saudi Arabia)
Psychotropics 2

24 Non-Persistence with Antidepressant Therapy in the Quebec Youth [327]
    Marie Tournier, Yola Moride, Guillaume Galbaud du Fort, Thierry Ducruet. (Canada)

25 Confounding by Indication in the Treatment of Patients with Alzheimer’s Disease [328]
    Antoine Pariente, Patrice Verpillat, Annie Fourrier-Reglat, Nicholas Moore. (France)

26 Characteristics and Outcomes in Hospitalized Patients Treated with Intramuscular Antipsychotics: Analysis of a US Hospital Database [329]
    Karen C Holdridge, William B Saunders, Kenneth Hornbuckle, John Polzer, John Houston, Sebastian Sorsaburu. (United States)

27 A Cohort Study of Atomoxetine and Cerebrovascular Outcomes in Adults [330]
    John D Seeger, Donnie Funch, Karen C Holdridge, Joachim Wernike, Shao Zhu, Alexander M Walker. (United States)

28 Hospitalization and Medication Use in a Cohort of 8,129 Rapid and Non-Rapid-Cycling Bipolar Youths [331]
    Ruby Castilla-Puentes. (United States)

29 Channelling of Aripiprazole to More Complex Psychiatric Patients [332]
    Rogier van der Hulst, Joost Jan Stolker, Gerard WK Hugenholtz, Toine CG Egberts, Elbert R Heerding. (Netherlands)

30 Type of Antidepressant Therapy and Risk of Type 2 Diabetes in People with Depression [333]
    Lauren C Brown, Sumit R Majumdar, Jeffrey A Johnson. (Canada)

31 Development of Type 2 Diabetes in Patients Taking Atypical Antipsychotic Agents: A Systematic Review [334]
    Lauren C Brown, Jeffrey A Johnson. (Canada)

32 SOHO Study: Follow up of a French Cohort of Schizophrenic Outpatients for 36 Months of Treatment [335]
    Isabelle Gasquet, Sandra Avoinet, Florence Chartier, Stephanie Tcherny-Lessenot, Jean Pierre Lepine. (France)

33 Factors Associated with Remission in Schizophrenia: 36-Months Results from the French Cohort of the Schizophrenia Outpatients Health Outcomes (SOHO) Study [336]
    Isabelle Gasquet, Sandra Avoinet, Florence Chartier, Stephanie Tcherny-Lessenot, Jean-Pierre Lepine. (France)

34 No Increased Cardiac Risk with Citalopram Use in Normal Practice Compared with Other Antidepressants in a General Practice Reseach Database (GPRD) Cohort [337]
    Patrice Verpillat, Delphine Saragoussi, Nicolas Despiegel, Mondher Touni, Dominique Milea. (France)

35 Association Between Antidepressant Drugs and Persistent Pulmonary Hypertension in Newborns in the UK-Based General Practice Research Database: A Cohort Study of Mother-Baby Linked Pairs [338]
    Tarek A Hammad, Sigal Kaplan, David J Graham, Judy A Staffa, Cynthia J Kornegay, Susan McCune, Hany Aly. (United States)

36 Use of Psychotropic Drugs in Extremadura (Spain) [339]
    Diana González-Bermejo, Félix Fernández-Bermúdez, Galo A Sánchez-Robles, Leopoldo Elvira-Peña, Ramona Mateos-Campos. (Spain)

37 Drug Utilisation of Neuropsychiatric Drugs in Children: A Multinational Study within the TEDDY Project [340]
    Macey L Murray, Antje C Neubert, Gino Picelli, Miriam CJM Sturkenboom, Katia MC Verhamme, Adriana Ceci, Carlo Giaquinto, Alfredo Nicolosi, Ian CK Wong. (United Kingdom)

38 Treatment Adherence to ChEIs Medications [341]
    Lucie Blais, Sylvie Perreault, Jean-Christophe Leroux, Marie-Jeanne Kergoat. (Canada)

39 Risk of Neuroleptic Malignant Syndrome Associated with Use of Antipsychotics in Patients with Bipolar Disorder: A Population-Based Case-Control Study [342]
    Yan Chen, Jeff J Guo, Nick C Patel. (United States)

40 Association Between Use of Antidepressant Drugs and Ischemic Stroke in Elderly Persons [343]
    Gianluca Trifirò’, Roelof Risselada, Achille P Caputi, Bruno Ch Stricker, Miriam CJM Sturkenboom. (Netherlands)
Cancer

41 Use of Antidepressants and Risk of Lung Cancer – A Nested Case-Control Study [344]
Sengwee Toh, Luis A García Rodríguez, Sonia Hernández-Díaz. (United States)

42 Cancer Incidence among Patients with and without Atopic Dermatitis in the UK [345]
Alejandro Arana, Charles E Wentworth, Eulogio Conde, Carlos Fernandez-Vidaurre, Raymond Schlienger, Felix M Arellano. (Spain)

43 Treatment Differences by Age in a Large U.S. Medical Claims-Based Cohort of Lung Cancer Patients [346]
Lisa Wang, Timothy Dube, Paula O’Connor, Wei Dong. (United States)

44 Gastrointestinal Bleeding Events in Cancer Patients Treated with Chemotherapy and Anti-Emetic Drugs [347]
Alexandra C Frost, Annette B Beiderbeck, Maria O Wishart, Jerzy E Tyczynski. (United States)

45 Application of Large Community-Based Cohort Study to Further Define Benefit-Risk Profile of Newly Approved Product – A Study of Bevacizumab (Avastin, BV) [348]
W Dong, D Purdie, M Kozloff, S Sarkar, M Sugrue. (United States)

46 A Retrospective Comparison of the Safety Profiles of High-Dose Imatinib and Dasatinib in Chronic Myeloid Leukemia (CML) Patients [349]
Erick Moynier, Lisa Pinheiro, Victoria Bargsht, Denise Williams, Augusta Salvado, Mei Sheng Duh. (United States)

47 Characteristics of Patients in a Post Marketing Osteosarcoma Surveillance Study [350]
Kirk D Mickiiff, Alicia W Gilsenan, Rebecca D Martin, Daniel N Masica, Elizabeth B Andrews. (United States)

48 Extent of: (1) Nausea and Vomiting and (2) Gastrointestinal Bleeding in Cancer Patients Treated with Chemotherapy: Results from Pooled Clinical Trials Data [351]
Annette B Beiderbeck, Liaquat Ali, Andy M Lawton, Jerzy E Tyczynski. (United States)

50 A Cohort Study of the Risk of Cancer in Regranex (Becaplermin) Users and Matched Comparators [353]
John D Seeger, Daniel Fife, Najat Ziyadeh, Alexander M Walker. (United States)

51 Improved Renal Function in Patients Switched from Intravenous (IV) Zoledronic Acid to IV Ibandronate: A Retrospective Review of Medical Records [354]
Ingo J Diel, Rudolf Weide, Hubert Köppler, Lucia Antrás, Michael Smith, Jesse Green, Neil Wintfeld, Maureen Neary, Mei Sheng Duh. (United States)

Pulmonary/Respiratory

52 Montelukast Plus Fluticasone in Comparison to Salmeterol Plus Fluticasone in Chronic Bronchial Asthma: A Systematic Meta-Analytical Review of the Randomized 48-Week Evidence of Clinical Efficacy and Safety [355]
Karl J Krobot, J Christian Virchow. (Germany)

53 Respiratory Drug Use in Children: A Multinational Database Study in the TEDDY Project [356]
Miriam Sturkenboom, Katia Verhamme, Macey Murray, Antje Neubert, Gino Picelli, Carlo Giaquinto, Alfredo Nicolosi, Ian Wong, Adriana Ceci. (Netherlands)

54 Rare Events and Exposures: Long-Acting Beta2-Agonists and Risk of Asthma-Related Mortality in Medicaid Enrollees [357]
Kourtney J Davis, Rachael L DiSantostefano, Richard Beasley, Anne Fuhlbrigge, Cheryl L Walker, David Miller, Patricia Tennis. (United States)

55 Obstructive Pulmonary Diseases: Retrospective Medical Records Represent Valuable Source Data for Evaluation of Longterm Medical Outcomes [358]
Tarja Laitinen, Juho Schultz, Petri Palmu, Eeva Reissell, Asta Pirskanen, Mika Salonoja, Timo Kunnas, Pentti Tukiainen, Tari Hahtela, Ari Lindqvist. (Finland)

56 Palivizumab Utilization and Hospitalizations Related to Respiratory Syncytial Virus Infections among Florida Medicaid Recipients [359]
Christian Hampp, Almut G Winterstein, Arwa Saldi, Miriam Schauff. (United States)
57 Health and Economic Impacts of Different Approaches to Disease Management for Adults with Asthma [360]
Shih-Yin Chen, Matthew Maciejewski, David Au. (United States)

58 Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Risk and Outcome of Pneumonia [361]
Ewoudt MW van de Garde, Henrik Endeman, Vera HM Deneer, Douwe H Biesma, Fakhredin A Sayed-Tabatabaei, Henk JT Rufen, Hubert CM Leukens, Jules MM van den Bosch. (Netherlands)

59 Chronic Obstructive Pulmonary Disease and Mortality Following Hip Fracture: A Population-Based Cohort Study [362]
Cynthia de Luise, Michael Brimacombe, Lars Pedersen, Henrik T Sorensen. (United States)

60 Extent of Uncontrolled Disease and Associated Medical Costs in Severe Asthma in the Netherlands [363]
Nancy S Breekveldt, Joelle A Erkens, Rene Aalbers, Marjo JT Van de Ven, Jan-Willem J Lammers, Ron MC Herings. (Netherlands)

61 Management of Acute Sinusitis: Result of a French Cohort Study [364]

62 Drug-Specific, Time-Dependent Risks of Serious Bacterial Infections Associated with TNF-a Antagonists [365]
Jeffrey R Curtis, Nivedita Patkar, Alyuan Xie, Carolyn Martin, Kenneth G Saag. (United States)

63 Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Severe Skin and Soft Tissue Complications in Patients with Varicella or Zoster Disease [366]
Yann Mikaeloff, Abbas Kezouh, Samy Suissa. (France)

64 Patterns and Correlates of Opioid Use in the U.S. Adult Population [367]
Judith P Kelly, Suzanne F Cook, Lynn Rosenberg, Allen A Mitchell, David W Kaufman. (United States)

65 Frequency and Characteristics of Subjects Switching from Traditional Non Steroidal Antiinflammarory Drugs to Coxibs: Data from the CADEUS Study [368]
Cecile Droz, Huong Nguyen Hoang, Fanny Depont, Regis Lassalle, Jeremy Jove, Patrick Blin, Nicholas Moore, Annie Fourrier-Reglat. (France)

66 Pain in Parkinson’s Disease: Pharmacoepidemiological Research into the Consumption of Analgesic Drugs [369]
Maryse Lapeyre-Mestre, Sabrina Grolleau, Robert Bourrel, Veronique Allaria-Lapierre, Robert Loi, Joelle Micallef-Roll, Christine Brefel-Courbon. (France)

67 Gastroprotection in Patients at Risk of Gastrointestinal NSAID Complications: Results of a General Practitioner Based Survey in France [370]
Gerard Thieffin, Thomas Borel, Marie Sophie Schwalm, Philippe Barthelemy. (France)

68 Select Medical Events in Lupus Patients Stratified by Therapeutic Intensity [371]
Stephen P Motsko, Bao-Anh Nguyen-Khoa, Pavel Napalkov, Earl L Goehring, Judith K Jones. (United States)

69 Recent Trends in Acetaminophen-Associated Overdoses in the United States, 2003 to 2005 [372]
Mary Willy, Syed R Ahmad, Yoo Jung Chang, Parivash Nourjah, Lauren Lee, Mark I Avigan. (United States)

70 Gastrointestinal and Thromboembolic Events with Valdecoxib: Case Series from a Prescription-Event Monitoring (PEM) Study in England [373]
Deborah Layton, Vanessa Marshall, Saad AW Shakir. (United Kingdom)

71 Anti-TNF Alpha Agents and Heart Failure Hospitalization in Patients with Rheumatoid Arthritis [374]
Soko Setoguchi, Sebastian Schneeweiss, Jerry Avorn, Daniel H Solomon. (United States)

72 Drug Utilisation of Analgesics and Anti-Inflammatory Drugs in Children: A Multinational Database Study within the TEDDY Project [375]
Antje Neubert, Macey L Murray, Miriam CJM Sturkenboom, Katia MC Verhamme, Gino Picelli, Alfredo Nicolosi, Carlo Giaquinto, Adriana Ceci, Ian CK Wong. (United Kingdom)

73 NSAID Switching and Short-Term Effects on Gastrointestinal Outcomes after the Withdrawal of Rofecoxib [376]
Sebastian Schneeweiss, Robert Glynn, Jerry Avorn, Mohammad Mammadni, Helen Mogun, Daniel Solomon. (United States)
74 Impact of Adverse Publicity and Withdrawal of Two COX-2 Inhibitors on Use of COX-2 Inhibitors and Non-Selective NSAID in Canada, 2000-2006 [377]
C Ineke Neutel. (Canada)

75 Evaluation of a Risk Management Plan to Minimize Concomitant Use of Ethinyl Estradiol/Drospirenone and Potentially Interacting Drugs [378]
Mara McAdams, Judy Stappa, Gerald Dal Pan. (United States)

76 A Risk Management Program for Ethinylestradiol/Drospirenone [379]
Jeanne Loughlin, John D Seeger, P Mona Eng, C Robin Clifford, Alexander M Walker. (United States)

77 Development and Validation of an Adverse Event Causality Assessment Tool for Use in Oncology Clinical Trials [380]
Megan Coombes, Mitch Levine, Som Mukherjee, Brenda Kowaleski, Jarold Cosby, Andrew Arnold. (Canada)

78 Causality Assessment of Adverse Events in Oncology Clinical Trials: A Qualitative Study [381]
Megan Coombes, Jarold Cosby, Mitch Levine, Brenda Kowaleski, Som Mukherjee, Andrew Arnold. (Canada)

79 A Meta-Analytic Comparison of the Incidence of Adverse Events for Capecitabine and Comparators for Breast and Colorectal Cancer [382]
Matthew W Reynolds, Sheila Crean, Kyle Fahrbach, Brian Sercus, Susan Zelt. (United States)

80 The Relationship between Two Different Methods – Bedside Recording and Computerised Screening – for the Identification of Drug Interactions [383]
Hege Salvesen Blix, Kirsten K Viktil, Tron A Moger, Aasmund Reikvam. (Norway)

81 Risk Management of Unapproved Drugs in Japan: An Academic Activity for Safety Data Exchange Via the Internet [384]
Tsugumichi Sato, Takahiro Kiuchi, Noriaki Aoki, Hikaru Watanabe, Kiyohito Kubota. (Japan)

82 Quantitative Risk-Benefit Analysis of Alosetron in Irritable Bowel Syndrome: A Patient-Level Meta-Cohort Analysis [385]
Larry D Lynd, Lindsey Colley, Mehdi Najafzadeh, Mark J Sculpher, Andrew R Willan, Reed F Johnson, Semra Ozdemir. (Canada)

83 Frequency, Nature and Severity of Medication Use Related Problems among Medical Outpatients in a Nigerian Tertiary Care Setting [386]
Kazeem Yusuff. (Nigeria)

84 Development of Canadian Safety Indicators for Medication Use [387]
Rita Nigam, Neil J MacKinnon, U David, Nicole R Hartnell, Adrian R Levy, Mary Ellen Gurnham, Tiffany T Nguyen. (Canada)

Syed Imran Haider, Kristina Johnell, Mats Thorslund, Johan Fastbom. (Sweden)

86 CONSULTENOS Program. Information to the Patient and Medication Related Problems Prevention at Discharge [389]
M Angeles Pardo-Lopez, Teresa Aznar-Saliente, Enrique Soler- Company. (Spain)

87 Reliability of a Method for the Assessment of Medication Errors Related Adverse Events [390]
Jasperien E van Doormaal, Peter GM Mol, Rianne J Zaal, Patricia MLA van den Bermt, Antoine CG Egberts, Jos GW Kosterink, Flora M Haaijer-Ruskamp. (Netherlands)

88 Polypharmacy among Elderly U.S. Nursing Home Residents by Race: Results from the 2004 National Nursing Home Survey [391]
Lisa L Dwyer. (United States)

89 Adverse Drugs Events (ADE) Analysis in Comunidad Valenciana Detected through Minimum Basic Data Set (MBDS) [392]
Enrique Soler-Company, Raul Ferrando, Rocio Romero, Julia Calabuig, Antonio Gonzalez. (Spain)

90 Survey on Medication Administration Via Enteral Feeding Tube: Practice and Knowledge [393]
Raid Al-Sabri, Elizabeth Worthing, Mohamed Al-Ghafri, Ibrahim Al-Zakwani. (Oman)

91 The Use of Statistical Significance by ISPE [394]
Michele M Jara, Stephan F Lanes. (United States)

92 The Effect of Double-Checking of Filled-Prescriptions in Reducing Potential Dispensing Errors at Outpatient Pharmacy in Sultan Qaboos University Hospital, Oman [395]
Wail H Al-Naeeem, Amna Al-Hashar, Aqeela Taqi, Kassim Al-Riyami. (Oman)
| 93 | Adverse Drug Events among Adults in Emergency Departments, Newfoundland and Labrador, Canada: A Preliminary Analysis [396] | Khokan C Sikdar, Don MacDonald, Reza Alaghehbandan, Brendan Barret, Kayla D Collins. (Canada) |
| 95 | Interprofessional Continuing Education for Management of Chronic Non-Cancer Pain [398] | Michael Allen, Bev Zwicker, Marco Chiarot. (Canada) |

**Pharmacovigilance 1**

| 96 | Self-Reported Adverse Effects and Adherence in Patients on Antiretroviral Therapy in Pretoria [399] | Ntambwe N Malangu, George G Muntingh, Wimpy W du Plooy. (South Africa) |
| 97 | Gemcitabine & Radiation – Drug Profiling for Assessment of Treatment Combination [400] | Andrzej Czarnecki. (United Kingdom) |
| 98 | Trends in the Quality of Spontaneous Reports from 1990 to 2005 [401] | Isaac W Hammond, Donna S Rich, Susan Ruane-Dao, Barbara Jensen-Carpenter. (United States) |

| 100 | Resources Required to Investigate the Results of Disproportionality Analyses Using Various Configurations [403] | S Bailey, M Cook, R Azadian, P Huber, M Blum, D Hembekides, M Kelly, M Langley, A Verticelli, C Schubert, M May, A Singh. (United States) |
| 101 | On Using Clinical Trials Data to Predict Postmarketing Signals of ADRs [404] | Bharat T Thakrar, Karen S Wilcock, Alan Nevitt, William DuMouchel. (Switzerland) |

| 104 | The Weber Curve Revisited: Temporal Changes in Reporting Rate of Newly Marketed Drugs [407] | Eugène van Puijenbroek, Mark de Groot, Kees van Grootheest. (Netherlands) |
| 105 | Mortality Due to Ischaemic Heart Disease (IHD) in a Cohort of Tadalafil Users Observed for 12 Months: Results from a Prescription-Event Monitoring Study [408] | L Hazell, V Cornelius, L Wilton, S Shakir. (United Kingdom) |

| 106 | A Study on Spontaneous Reporting of Adverse Drug Reactions (ADRs) Related Hospital Admissions in Three Tertiary Care Indian Hospitals [409] | Parthasarathi Gurumurthy, Ramesh Madhan, Rajesh Radhakrishnan. (India) |

| 107 | Validation of an Australian Claims Database to Detect Adverse Events Post Drug Therapy [410] | Nicole Pratt, Elizabeth Roughead, Robert Peck, Andrew Gilbert. (Australia) |
| 109 | Reporting of Adverse Drug Reactions May Be Influenced by Feedback to the Reporting Doctor [412] | Susanna M Wallerstedt, Gertrud Brunlof, Marie-Louise Johansson, Carina Tukukino, Lars Ny. (Sweden) |

| 111 | Spontaneously Reported Suspected Adverse Drug Reactions in Association with Complementary and Alternative Medicine Products [414] | Ingela Jacobsson, Anna K Jonsson, Barbro Gerden, Cecilia Axling, Staffan Hägg. (Sweden) |


| 113 | Event Rates of Hospitalization-Associated Convulsions in Dialysis Patients in the United States Renal Data System [416] | Victor Gastañaga, Scott Stryker, Atsuko Shibata, Peter Mccroskery, T Christian Mix, Sean Zhao. (United States) |
114 Biologic Fibrin Sealant Safety Surveillance [417]
Kathryn O’Connell, Kimberly Lindsey, Robert Wise. (United States)

115 Drug Safety of Thiazolidinediones in France [418]
Stephanie Berthet, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. (France)

116 Withdrawn by Author [419]

117 Effect of Well-Established Drug-Event Associations on the Generation of New Signals in Spontaneous Reporting Databases [420]
Antoine Pariente, Paul Avillach, Frantz Thiessard, Chada Miremont-Salame, Annie Fournier-Reglat, Françoise Haramburu, Nicholas Moore. (France)

118 Rates and Determinants of Reinitiating Antihypertensive Therapy after Prolonged Stoppage [421]
Boris LG van Wijk, Jerry Avorn, Daniel H Solomon, Olaf H Klungel, Eibert R Heerdink, Anthonius de Boer, Alan M Brookhart. (Netherlands)

119 A Cross-National Study of Persistence of Antihypertensive Medication Use in the Elderly [422]
Boris L Van Wijk, William H Shrank, Olaf H Klungel, Jyotsna Dhall, Raisa Levin, Jerry Avorn. (Netherlands)

120 Community-Based Global Cardiovascular Risk Reduction with Pharmacotherapy for Modifiable Risk Factors in High-Risk Patients [423]
Pendar Farahani, Mitchell Levine. (Canada)

121 Classification of Hyperlipidemia from Automated Primary Care Data in the UK and France [424]
Andrew Maguire, Marie Sophie Schwalm, Ian Douglas, Liam Smeeth. (United Kingdom)

122 Pharmacoepidemiology of Antihypertensive Drugs in Bishkek [425]
Zulfiya T Radjapova, Aynagul S Djumagulova, Andrew G Polupanov. (Kyrgyzstan)
123 Beta-Blockers in Heart Failure: The Influence of the Specialty of the Prescriber on Clinical Outcomes [426]  
Mathieu Bernier, Marc Dorais, Agnes Rakel, Jean-Francois Boivin, Odile Sheehy, Jacques LeLorier. (United States)

124 Cardiac Drug Therapy and Clinical Outcomes Following Coronary Artery Bypass Grafting [427]  
Dimitri Kalavrouziotis, Karen J Buth, Roger JF Baskett. (Canada)

125 Non-Persistent Use of Antihypertensive Drugs Increases Risk of Hospitalizations for Stroke by Nearly 20% [428]  

126 Persistent Use of Antihypertensive Drugs Leads to a Two Times Increased Chance of Blood Pressure Goal Attainment in Stage 2 Antihypertensive Patients [429]  

127 Hepatic Events Reported in the Rosuvastatin Prescription Event Monitoring Study [430]  
R Kasliwal, L Wilton, S Shakir. (United Kingdom)

128 Thirty-Day Mortality and Acute Renal Failure in Patients Treated with Aprotinin or Tranexamic Acid during Cardiac Surgery [431]  
Flemming Sondergaard, Vibeke E Hjortdal, Carl-Johan Jakobsen. (Denmark)

129 Atherosclerotic Cardiovascular Disease, Statins and Subsequent Risk of Venous Thromboembolism: A Population Based Case Control Study [432]  
Kirstine K Soegaard, Erzebet Puho, Lars Pedersen, Soren P Johnsen, Paolo Prandoni, John A Baron, Henrik T Sorensen. (Denmark)

Hematological

130 Blood Use by Inpatient Elderly Population in the United States [433]  
Mikhail Menis, Dale R Burwen, Kathryn O’Connell, Steven A Anderson. (United States)

Vaccines

131 Improving the Efficiency of Testing the Efficacy of a Portfolio of HIV Vaccines and Microbicides [434]  
Paul M Coplan. (United States)

132 Incidence of Herpes Zoster: Performance of Databases Versus Medical Charts and Implication for Surveillance after Vaccine Introduction [435]  
Patricia Saddier, Barbara Yawn, Carolyn Harley, Lina Sy. (United States)

Anti-Infectives

133 Re-Evaluation for the Safety of Levamisole in Post-Marketing: Literature Survey [436]  
Rong-yuan Zheng, Xue-zhi Yang, Zhen-guo Zhu, Wei-yong Ying. (China)

134 Antibiotic Prescribing to Children in UK General Practice: Changes in Indications over Time [437]  
Paula L Thompson, Ruth Gilbert, Paul Long, Mike Sharland, Ian CK Wong. (United Kingdom)

135 A Clinical Review on 557 Cases of In-Patient with Drug Eruption [438]  
Ning Ou, Tian-nan Zhang. (China)

136 Adverse Effects Associated with Prolonged Antibiotic Use [439]  
Sharon B Meropol, K Arnold Chan, Zhen Chen, Jonathan A Finkelstein, Sean Hennessy, Ebbing Lautenbach, Richard Platt, Stephanie D Schech, Deborah Shatin, Joshua P Metlay. (United States)

137 Early Recognition of Clinically Relevant Antiretroviral Non-Adherence [440]  
Robert Gross, Warren B Blicher, Hao Wang, Jennifer Chapman. (United States)

138 Effect of Antiretroviral Class on Hepatotoxicity in HIV-Infected Patients [441]  
Mary E Ritchey, Samantha A St.Laurent, Mark W Russo, Michele L Jonsson-Funk. (United States)

139 Antifungal Prescription Practices of Canadian Intensivists in Patients with a Clinical Suspicion of VAP and Positive Candida Airway Cultures [442]  
M-S Delisle, MM Perreault, DR Williamson, M Albert, X Jiang, DK Heyland. (Canada)

140 Increase of Breast Cancer Risk in Association with Exposure to Antibiotics [443]  
Hani M Tamim, James Hanley, Ali Hajeer, Jean-Francois Boivin, Jean-Paul Collet. (Saudi Arabia)

141 Hematological Safety of the Association (Pyrimethamine-Sulfadoxine Versus the Two Components Pyrimethamine + Sulfadiazine: A 18 Years Follow Up [444]  
Carole L Frances, Isabelle M Villeda, Cathy C Chemla, Jean-Michel Pinon, Thierry C Trenque. (France)
Women’s Health

1 Prevalence of Oral Contraceptive Users for Birth Control and Their Characteristics in a Japanese Women Cohort [445]
   Kunihiko Hayashi, Toshiharu Fujita, Hideki Mizunuma, Kota Katanoda, Yasuhiro Matsumura, Shosuke Suzuki, Toshiro Kubota, Takeshi Aso. (Japan)

2 Interim Results from the International Active Surveillance Study of Women Taking Oral Contraceptives (INAS OC) [446]
   Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann. (Germany)

3 Effect of Fetal Sex on Maternal Asthma during Pregnancy [447]
   Faranak Firouzi, Lemiere Catherine, Beauchesne Marie-France, Ducharme M Francine, Forget Amelie, Blais Lucie. (Canada)

4 The Prevalence of Endometriosis and Associated Risk Factors [448]
   Helen E Seaman, Karen Ballard, Jeremy Wright, Corinne S de Vries. (United Kingdom)

Hormones/Reproductive Agents

5 The Safety of Oral Hormone Replacement Therapy under Real Life Conditions: Interim Results from the EURAS-HRT Study [449]
   Juergen C Dinger, Anita Assmann, Doerthe Kuehl-Habich. (Germany)

6 Exenatide-Associated Acute Pancreatitis [450]
   Syed R Ahmad, Joslyn Swann. (United States)

Pediatric Pharmacoepidemiology

7 Drug Utilisation Study of Antiepileptic Drugs in Girls of Child-Bearing Age Potential – Preliminary Results Using the General Practice Research Database (GPRD) [451]
   Ruth Ackers, Macey L Murray, Frank MC Besag, Ian CK Wong. (United Kingdom)

8 Use of Drugs Affecting the Renin-Angiotensin System in the Very Young to Late Adolescence. An Analysis Using the Swedish Prescription Drug Register [452]
   Susan W Andersson, Andrejs Leimanis, Saga Johansson. (Sweden)

9 Olanzapine in the Treatment of Adolescents with Bipolar Mania; 26-Week Open-Label Extension [453]
   Mauricio Tohen, Ludmila Kryzhanovskaya, Gabrielle Carlson, Melissa DelBello, Janet Wozniak, Robert Kowatch, Karen Wagner, Robert Findling, Daniel Lin, Carol Robertson-Plouch, Wen Xu, Ralf Dittmann, Joe Biederman. (United States)

10 Olanzapine Efficacy and Tolerability in Adolescents with Schizophrenia: Results from an Open-Label Extension Phase [454]
   Carol Robertson-Plouch, Ludmila Kryzhanovskaya, Charles Schulz, Christopher J McDougle, Jean A Frazier, Wen Xu, Janice Carlson, Mauricio Tohen. (United States)

11 Epidemiology of Antipsychotic Prescribing for Children and Adolescents in the UK [455]
   Fariz A Rani, Macey L Murray, Patrick J Byrne, Ian CK Wong. (United Kingdom)

12 Diagnostic Patterns of Atopic Conditions in Children: Administrative Health Databases Study from Quebec [456]
   Marie-Josee Martel, Jean-Luc Malo, Evelyne Rey, Sylvie Perreault, Marie-France Beauchesne, Amelie Forget, Lucie Blais. (Canada)

13 Patterns of Antipyretic-Analgescic Use among U.S. Children Are Changing: Results from the Slone Survey [457]
   Louis Vernacchio, Judith P Kelly, David W Kaufman, Lynn Rosenberg, Allen A Mitchell. (United States)

14 Adverse Drug Reaction Reporting in Children – The Teddy Project [458]
   Katia MC Verhamme, Patty M Elferink-Stinkens, Macey L Murray, Antje Neubert, Alfredo Nicolosi, Ian Wong, Adriana Ceci, Bruno HCh Stricker, Miriam CJM Sturkenboom. (Netherlands)

15 General Drug Utilization in Children – A Multinational Database Study in the TEDDY Project [459]
   Miriam CSturkenboom, Katia M Verhamme, Macey L Murray, Antje Neubert, Gino Picelli, Carlo Giaquinto, Alfredo Nicolosi, Ian Wong, Adriana Ceci. (Netherlands)

16 Population-Based Databases for Paediatric Medicine Research in Europe: A TEDDY Appraisal [460]
   Antje Neubert, Macey L Murray, Miriam CJM Sturkenboom, Katia MC Verhamme, Alfredo Nicolosi, Carlo Giaquinto, Adriana Ceci, Ian CK Wong. (United Kingdom)

17 Efficacy and Safety of Omega-3 Fatty Acid Interventions among Children [461]
   Beth L Nordstrom, Corey A Probst, Douglas Kling, Matthew W Reynolds. (United States)
<table>
<thead>
<tr>
<th>Poster Session C</th>
<th>Wednesday, August 22</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 Pediatric Prescription-Event Monitoring (PEM) and Risk Management: Results of a Modified PEM Study on Lamotrigine and Vigabatrin [462] B Aurich-Barrera, L Wilton, D Brown, S Shakir. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td><strong>CNS/Neurological</strong></td>
<td></td>
</tr>
<tr>
<td>20 The Association of Weight Change with Depression [464] Gillian C Hall, Alex McMahon. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>21 Problems with Onset of Multiple Sclerosis Based on Hospital Discharge Data [465] Mette Nørgaard, Jacob Jacobsen, Jamie Gradus, Timothy L Lash, Henrik T Sørensen. (Denmark)</td>
<td></td>
</tr>
<tr>
<td>22 Off-Label Use of Atypical Antipsychotics among Patients with Bipolar Disorder in Medicaid [466] Yonghua Jing, Paul E Keck, Jeff J Guo, Hong Li, Xing Li, Nick C Patel. (United States)</td>
<td></td>
</tr>
<tr>
<td>23 Characteristics Associated with Non-Acceptance of Antidepressant Treatment [467] Erica CG Van Geffen, Rolf Van Hulten, Marcel L Bouvy, Antoine CG Egberts, Elbert R Heerdink. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>24 Levetiracetam Continuation During One Year Real-Life Use in France, the EULEV Study [468] C Droz, C Dureau, H Vespignani, C Marchal, C Pollet, J Jove, N Moore, A Fourrier-Reglat. (France)</td>
<td></td>
</tr>
<tr>
<td>25 Antihypertensive Therapy and the Risk of Parkinson's Disease [469] Claudia Becker, Susan S Jick, Christoph R Meier. (Switzerland)</td>
<td></td>
</tr>
<tr>
<td>26 Persistence of Cholinesterase Inhibitor Therapy in a Population-Based Cohort of Patients with Alzheimer's Disease [470] Joseph E Amuah, David B Hogan, Michael Eliaziw, Alison Supina, Patricia Beck, Winnane Downey, Colleen J Maxwell. (Canada)</td>
<td></td>
</tr>
<tr>
<td>27 Baseline and Ongoing Psychiatric Comorbidity in Women Diagnosed with Stress Urinary Incontinence in the General Practice Research Database [471] Indiana M Strombom, Frank P DeLisle, Richard C Bump, John P Polzer, Kenneth Hornbuckle. (United States)</td>
<td></td>
</tr>
<tr>
<td>28 Prescription and Utilization Patterns of Adjunct Treatments to Levodopa in Parkinson's Disease [472] Delphine Saragoussi, Benoit Rive, Dominique Milea, Mondher Toumi, Bruno Fantino, Patrice Verpillat. (France)</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular 2</strong></td>
<td></td>
</tr>
<tr>
<td>29 Assessment of Interaction between Aspirin and Ibuprofen/NSAIDs on Cardiovascular Effect [473] Ching-Lan Cheng, Yea-Huei Yang Kao, Swu-Jane Lin. (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>30 A Propensity Score Controlled Cohort Study To Investigate the Effects of Statins [474] Ian J Douglas, Liam Smeeth, Stephen J Evans. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>31 Cost-Effectiveness of Statins for Primary Prevention of Coronary Heart Disease in Japan [475] Shunya Ikeda, Makoto Kobayashi. (Japan)</td>
<td></td>
</tr>
<tr>
<td>32 Antihyperlipidemc Medication Use among US Adults, 1988-2002 [476] Ryne Paulose-Ram, David A Lacher, Qiuping Gu, Margaret D Carroll. (United States)</td>
<td></td>
</tr>
<tr>
<td>34 Cholesterol Level and Subsequent Use of Statins: A Prospective Study of 6700 Men and Women Aged 59-61 Years [478] Randi Selmer, Aage Tverdal, Svetlana Skurtveit, Kari Furu. (Norway)</td>
<td></td>
</tr>
<tr>
<td>35 Age and Gender Specific Incidence of Hospitalization for Digoxin Intoxication [479] Albert-Jan LHJ Aarnoudse, Jeanne P Dieleman, Bruno HCh Stricker. (Netherlands)</td>
<td></td>
</tr>
<tr>
<td>36 Determinants of Cholesterol and Triglycerides Recording in Patients Treated with Lipid Lowering Therapy in UK Primary Care [480] Andrew Maguire, Ian Douglas, Liam Smeeth, Mary Thompson. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>37 Patterns of Cholesterol Levels in Patients Treated with Lipid Lowering Drugs in UK Primary Care [481] Andrew Maguire, Ian Douglas, Liam Smeeth. (United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Use of Lipid-Lowering Drugs in the Defined Swedish Population of 9 Million Inhabitants</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>40</td>
<td>Validation of Diagnoses of Hospitalizations Due to Peptic Ulcer Complications: Results Using the TennCare Database</td>
</tr>
<tr>
<td>42</td>
<td>Risk of Impaired Renal Function after Colonoscopy: A Cohort Study in Patients Receiving Either Oral Sodium Phosphate or Polyethylenglycol</td>
</tr>
<tr>
<td>43</td>
<td>Proton Pump Inhibitor (PPI) Use and Pneumonia Risk in Veteran Patients with and without Co-Morbidities</td>
</tr>
<tr>
<td>44</td>
<td>A Quantitative Analysis of Spontaneous Reports of Muscle Injury with Proton Pump Inhibitors</td>
</tr>
<tr>
<td>45</td>
<td>Prescribing in Dyspepsia before and after the Introduction of NICE Guidelines</td>
</tr>
</tbody>
</table>

### Gastrointestinal

**What does Lilly provide to patients?**

**Answers.**

We impact lives by delivering answers to some of the world’s toughest health care questions. And, with over a century of experience behind our name, there is no one better prepared than Eli Lilly and Company to tackle these questions and the challenges of our changing industry.

We have laid the foundation for continued success with a rich pipeline of best-in-class, first-in-class pharmaceutical products and a collaborative culture that supports people in reaching their greatest potential. It is through the diverse perspectives and accomplishments of our people that we are able to touch the lives of patients by providing the medicines that will enable them to lead longer, healthier lives.

Today and in the future, Lilly will provide “Answers That Matter.”

[www.lilly.com](http://www.lilly.com)

Lilly

Answers That Matter.
46 Researchers Were Able to Obtain 78% of Requested Hospital Records To Validate Medicaid and Medicare Claims While Complying with HIPAA [490]
Sean Hennessy, Charles E Leonard, Warren B Bliker. (United States)

47 Potential for Detection Bias: Diabetes Therapies and Colorectal Neoplasia [491]
James D Lewis, Angela M Capra, Ninah S Achacoso, Assiamira Ferrara, TR Levin, Charles P Quesenberry, Jr., Laurel A Habel. (United States)

48 Validity of Benzodiazepine Exposure Measured from Patient Interview: Data from the 3C Cohort [492]
Pernelle Noize, Antoine Pariente, Jonathan Sokolowski, Nicholas Moore, Annie Fourrier-Reglat. (France)

49 Strengths and Limitations of Drug Abuse Warning Network Data Used in a Surveillance Study [493]
Kirk Midkiff, Catherine Johannes, Aparna Mohan. (United States)

50 Measuring Quality of Care – Laboratory Monitoring for Rheumatoid Arthritis [494]
Jyotsna Mehta, Jessica Agnew-Blais, Jeffrey Neil Katz, Jonathan Scott Coblyn, Daniel Hal Solomon. (United States)

51 Sample Size Calculation for an Epidemiologic Study with an Unknown Background/Expected Rate or Proportion [495]
Kui Huang, Quazi Ataher. (United States)

52 A Comparison of Prescription Refill Adherence and Patients’ Report To Identify Non-Adherence with Inhaled Corticosteroids [496]
TT Menckeberg, ML Bouvy, M Bracke, AA Kapteijn, R Horne, HGM Leufkens, JAM Raaijmakers. (Netherlands)

53 Using Structured Audits To Increase the Percentage of Patients Achieving an Agreed Lipid Lowering Target [497]
Philip S Woodvine, Stephen R Chapman. (United Kingdom)

54 Feasibility of Conducting a Pragmatic Cluster Cohort Study Using Administrative Databases to Evaluate the Effectiveness of an Osteoporosis Workshop to Family Physicians [498]
Marie-Claude Laliberte, Sylvie Perreault, Alice Dragonir, Johanne Goudreau, Isabel Rodrigues, Lucie Blais, Nicole Damestoy, Diane Corbeil, Lyne Lalonde. (Canada)

55 Sensitivity of an Instrumental Variable Analysis to Treatment Effect Heterogeneity and Violations of Structural Assumptions [499]
M Alan Brookhart, Sebastian Schneeweiss. (United States)

56 Implementation Research: The Veterans’ Medicines Advice and Therapeutics Education Services (Veterans’ MATES) [500]
Andrew Gilbert, Jodie Hillen, Elizabeth Roughead, John Barratt. (Australia)

57 Patient Specific Provider Feedback Effective in a Range of Target Conditions [501]
Andrew Gilbert, Nicole Pratt, Emmee Ramsay, Elizabeth Roughead, Robert Peck. (Australia)

58 Initial Treatment Effectiveness of Acute Sinusitis in a Representative National Cohort [502]

59 Effectiveness of Atazanavir in HIV-Infected Patients [503]
Enrique Soler-Company, Amparo Rocher, Marta Caja, Manuela Gonzalez, Inmaculada Segui. (Spain)

60 Understanding and Assessing Registries for Evaluating Patient Outcomes [504]
Nancy A Dreyer, Elise Berliner, Scott R Smith, Rosemarie Hakim, Richard Gliklich. (United States)

61 Use of a Fully Sequential Design to Assess Post-Licensure Vaccine Effectiveness of a Hepatitis B Vaccine Regimen [505]
Walter Straus, Monique Bulotsky, Suzanne Garland, Martin Wright, Hassan Lakkis, Richard Doherty. (United States)

62 Descriptive Epidemiology, Patterns of Anticoagulant Use, and Outcomes among Patients with Atrial Fibrillation [506]
Dimitri Bennett. (United States)

63 Patterns and Predictors of Anticoagulant Use among Patients with Atrial Fibrillation [507]
Dimitri Bennett. (United States)

64 Prevalence of Lower Urinary Tract Symptoms (LUTS) in Men: Canadian Results from the Epic Study [508]
S Herschorn, L Valiquette, D Irwin, J-P Roussy, I Defoy. (Canada)
Prevalence of Overactive Bladder: Canadian Results from the Epic Study [509]
S Herschorn, L Valiquette, D Irwin, J-P Roussy, I Defoy. (Canada)

Fibrosis Progression among Patients Transplanted for HCV-Related Liver Disease: A Systematic Literature Review [510]
Nataliya Volkova, Ayman Ayoub. (United States)

Chronic Obstructive Pulmonary Disease in the General Population: Incidence, Morbidity and Mortality [511]
Luis A Garcia Rodriguez, Laura Barreales Tolosa, Mari-An Wallander, Saga Johansson. (Sweden)

Factors and Symptom Reporting between Fibromyalgia Patients and Referents. A Population-Based Case-Referent Study [512]
Karim Bjorkgren, Mari-An Wallander, Saga Johansson, Kurt Svardsudd. (Sweden)

SLEEP-i Study, a Multicountry Survey: Similarities and Differences in Socio-Demographic Characteristics and Quality of Life in Chronic Insomniacs [513]
Charles M Morin, Damien Leger, Makoto Uchiyama, Makoto Kobayashi, Isabelle Gilloteau, James K Walsh. (France)

Characteristics and Pattern of Treatment in Newly Diagnosed Patients with Anxiety and Depression in Primary Care [514]
Ana Ruigomez, Mari-An Wallander, Saga Johansson, Luis Alberto Garcia-Rodriguez. (Spain)

Cardiovascular Diseases’ Risk in Portugal [515]
Ana Macedo, Ana Santos, Carlos Perdigão. (Portugal)

Trends in Danish Nationwide Hospitalization Rates for Heroin, Methadone or Other Strong Analgesic Intoxications, 1998-2004 [516]
Steffen Christensen, Henrik F Thomsen, Helle Kieler, Scott Chavers, Anders Ekbom, Henrik T Sørensen. (Denmark)

Searching for the Right Research Data?
Take a look at the expanding family of MarketScan® Research Databases

- Inpatient, outpatient including drugs and linked data
- Commercially insured, Medicare, Medicaid
- Lab test results
- Health risk assessments
- Absence, short-term disability, workers’ compensation

The gold standard in high quality research data available for contracted research studies and as licensable databases, subsets, and online.

For details visit www.medstat.com
or call 1-866-301-5419
73 How Does Remission in Major Depressive Disorder Impact Resource Use in the UK? A General Practitioner Research Database (GPRD) Based Study [517]
Alan G Wade, Nicolas Despiegel, Natalya Danchenko, Delphine Saragoussi, Patrice Verpillat. (France)

74 Costs of Childhood Autism in Thailand [518]
Jutamas Suwan, Chondan Phunyamanee, Nujaree Khamduang, Penkarn Kanjanarat. (Thailand)

75 Evaluation of Stress Urinary Incontinence and Suicidality among Females in the General Practice Research Database [519]
Indiana M Strombom, Richard C Bump, Frank P DeLisle, John P Polzer, Kenneth Hornbuckle. (United States)

76 Factors Associated with Interview Completion Rates in a Surveillance Study of Osteosarcoma and Antecedent Exposures [520]
Alicia W Gilsenan, Kirk D Midkiff, Yun Wu, Rebecca D Martin, Daniel N Másica, Elizabeth B Andrews. (United States)

77 An Epidemiologic Study of Health Outcomes among Patients with Psoriasis [521]
Susan A Oliveria, Marianne Ulcickas Yood, Carmen Bozic, Sharon Hensley Alford, Karen Wells, Ellen Friedla, Dana L Sachs. (United States)

78 Epidemiology of Hypertriglyceridemia in Children [522]
Beth L Nordstrom, Corey A Probst, Douglas Kling, Matthew W Reynolds. (United States)

79 Projecting Diabetes Prevalence and Treatment Rates to the U.S. Employer-Insured Population [523]
Stella Chang, Leigh Hansen, William D Marder. (United States)

80 Abscess Outbreak with Mycobacterium massiliense Associated with Intramuscular Injection, Icheon, Korea, 2004-2005 [524]
Hwa Jung Kim, Seung-Mi Lee, Young-Gyoun Cho, Hong-Ji Song, Yoon-Hoh Kook, Byung-Joo Park. (Korea)

81 Time to Involve Nurses in the Program for Reporting Adverse Drug Reactions in Sweden? Attitudes among Physicians [525]
Elisabet Ekman, Martin Bäckström. (Sweden)

82 Drug Use Patterns and Polypharmacy among Elderly Adults in Germany [526]
Yong Du, Hildraud Knopf, Ludger Pientka, Ulrich Thiem, Christa Scheidt-Nave. (Germany)

83 Number Needed to Signal, a New Statistic for Signal Detection [527]
Rezaul Karim, Stephen L Klicewicz, Chuen L Yee. (United States)

84 Auricular and Renal Pharmacovigilance Data Are Linked through a Predictive Mechanistic Commonality [528]
B Marianne Verdel, Eugene P van Puijenbroek, Patrick C Souverein, Hubert GM Leufkens, Antonius CG Egberts. (Netherlands)

85 Choice of the Comparator for Signal Generation in Pharmacovigilance Databases: Impact on Detection Thresholds [529]
Antoine Pariente, Marie Didailler, Annie Fourrier-Reglat, Françoise Harmamburu, Nicholas Moore. (France)

86 Hypoglycaemia Associated with the Use of Angiotensin II Receptor Antagonists: A Safety Signal Generated by Confounding [530]
Fleur Gregoire, Antoine Pariente, Annie Fourrier, Françoise Harmamburu, Nicholas Moore. (France)

87 Lareb Intensive Monitoring, a Web Based System for Monitoring ADRs in the Postmarketing Phase [531]
Kees van Grootheest, Linda Härmark, Ingrid Oosterhuis, Eugène van Puijenbroek. (Netherlands)

88 Design Issues in Active Surveillance Studies: Experience from the EURAS Studies [532]
Juergen C Dinger, Anita Assmann, Lothar AJ Heinemann. (Germany)

89 Smile Plots to Identify Adverse Drug Reactions [533]
W Marieke Schoonen, Prof Stephen JW Evans, Prof Andrew J Hall. (United Kingdom)

90 A Tool for Computation and Comparison of Proportional Reporting Rates for Multiple Drugs over Time [534]
Keith Altman. (United States)

91 An Elevation If Reporting Rates for Numerous Fracture Events Associated with the Use of Enbrel® (Etanercept) [535]
Keith Altman. (United States)

92 Acute Meprobamate Self-Poisoning: A Survey of Five Years [536]
Olivier P Dautremay, Emmanuelle J Herlem, Denis L Lamiable, Guillaume B Hoiyze, Thierry C Trenque. (France)

93 Security of Atazanavir in HIV-Infected Patients [537]
Enrique Soler-Company, Amparo Rocher, Beatriz Martinez, Raul Ferrando, Juan Flores. (Spain)

94 Association between Venous Thromboembolism and Antipsychotics: A Population Based Case-Control Study [538]
Anna K Jönsson, Henrik T Sørensen, Erzébet Horváth-Puhó, Staffan Hägg. (Sweden)
95 Results from Data Mining in IMS Disease Analyzer Patient Records [539]
Andrew Bate, Niklas G Norén, Kristina Star, Johan Hopstadius, Ralph I Edwards. (Sweden)

96 Drug Interaction Signal Detection in Spontaneous Reports [540]
Johanna Strandell, Andrew Bate, Marie Lindquist, I Ralph Edwards. (Sweden)

97 A Novel Data Mining Approach for Detecting Signals of Adverse Drug Reaction (ADR) by Celecoxib Using Health Insurance Claims Database [541]
Nam-Kyong Choi, Seokyung Hahn, Ji-Sun Kim, Byung-Joo Park. (Korea)

98 Issues in Confounder Adjusted Adverse Drug Reaction Surveillance [542]
Johan Hopstadius, Niklas G Norén, Andrew Bate, Ralph Edwards. (Sweden)

99 An Evaluation of Data Mining by High Level Terms [543]
Mary Ann D Goss, Jack E Leitmeyer, Vinit Mathew, Jie Chen, Heidi P Lehman, Kristine E Shields. (United States)

100 Signal Volume: Thresholds and Statistics Create Huge Differences [544]
Victor V Gogolak, Sheila Weiss-Smith, Stephanie Chung, Guarav Deshpande. (United States)

101 An Automated Method to Eliminate Bias Induced by Co-Prescription in Safety Signal Generation Using Spontaneous Reporting Databases [545]
P Avillach, A Pariente, F Thiessard, G Miremont, A Fourrier, N Moore. (France)

102 Signal Detection of Visual and Hearing Adverse Events Associated with Imatinib Mesylate (Gleevec®) [546]
Sharon A Petronella, Victor Alexander, Gregg S Wilkinson. (United States)

103 Characteristics of Adverse Event Reporting for Narcotic and Non-Narcotic Analgesics [547]
Gaurav Deshpande, Sheila Weiss Smith, Anthony Tommasello, Linda Simoni-Wastila, Victor Gogolak. (United States)